MPP-ViiV Agreement Expanded: Aurobindo, Cipla and Viatris to Make Generic HIV Drug Cabotegravir
ViiV Healthcare and the Medicines Patent Pool (MPP) have expanded their voluntary licensing agreement for cabotegravir, enabling manufacturers such as Aurobindo, Cipla, and Viatris to develop, manufacture, and supply generic versions for the HIV treatment in 133 countries.
Global Pharma | 15/07/2025 | By Dineshwori | 500
Jubilant Ingrevia Appoints Kailash Ukhade as Vice President - Projects
Jubilant Ingrevia Ltd. has announced the appointment of Kailash Ukhade as Vice President – Projects, based in Bharuch.
Global Pharma | 15/07/2025 | By Dineshwori | 233
Evonik Opens New Medical Device Application Center in Shanghai to Serve Asian Market
The Evonik Shanghai Medical Device Center is designed to help manufacturers tackle complex challenges and accelerate innovation in medical technologies.
Global Pharma | 14/07/2025 | By Dineshwori | 229
Senores Pharmaceuticals Inks SPA to Raise Stake in Havix
Senores Pharmaceuticals Ltd. (SPL) has entered into a Share Purchase Agreement (SPA) with a public shareholder of Havix Group Inc., doing business as Aavis Pharmaceuticals (Havix), to acquire 6,730 equity shares — representing 2.97 percent of Havix’s total paid-up share capital.
Global Pharma | 14/07/2025 | By Dineshwori | 369
Cipla to Enter Weight Management Segment, Expands Focus on Oncology and CNS Therapies
Cipla is set to enter India’s growing weight management market as part of its broader strategy to expand across emerging therapeutic segments.
Global Pharma | 14/07/2025 | By Dineshwori | 238
Wockhardt Realigns US Operations to Focus on Innovative Portfolio, Exits Generic Pharma Segment
Wockhardt has announced a strategic realignment of its US operations, exiting the loss-making generics business to focus on its innovation-led priorities in novel antibiotics and biologics, marking a decisive shift toward building a differentiated, future-ready pharmaceutical enterprise.
Global Pharma | 11/07/2025 | By Mrinmoy Dey | 447
Novartis Signs Brain Delivery Deal With Sironax, Wraps pCPA Talks on Cosentyx Reimbursement
Novartis has signed an exclusive option agreement with Chinese biotech firm Sironax to potentially acquire its proprietary Brain Delivery Module (BDM) platform and concluded negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) on the public reimbursement of Cosentyx.
Global Pharma | 11/07/2025 | By Dineshwori | 299
Glenmark's IGI Signs Licensing Deal with AbbVie for Investigational Cancer Therapy
AbbVie to lead global development, manufacturing and commercialisation of Ichnos Glenmark Innovation’s (IGI) investigational cancer therapy ISB 2001 in North America, Europe, Japan, and Greater China, while Glenmark will take these roles in emerging markets.
Global Pharma | 11/07/2025 | By Dineshwori | 263
Celltrion Announces Three-Stage Strategy to Counter Trump's Pharma Tariff Plan
Celltrion has announced its response strategy to US President Donald Trump’s plan to impose tariffs on pharmaceuticals.
Global Pharma | 10/07/2025 | By Dineshwori | 497
MolecuLight Appoints Dr. Julia Wright, MD, FACP, as its New Chief Medical Officer
MolecuLight Inc. announced the appointment of Dr. Julia Wright, MD, FACP, as its new Chief Medical Officer (CMO). In this pivotal role, Dr. Wright will lead MolecuLight's global medical and clinical strategy.
Global Pharma | 10/07/2025 | By Manvi | 177
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy